Astellas Pharma Day

February 8, 2022 3:30 PM - 5:00 PM

MassBioHub, 700 Technology Square, 5th Floor Cambridge MA 02139

Add to Calendar 2/8/2022 3:30:00 PM 2/8/2022 5:00:00 PM Astellas Pharma Day Accelerate your biotech company, startup, or university’s innovation portfolio at our Astellas 2022 Pharma Day on February 8.

MassBio’s Pharma Days® are unparalleled opportunities for emerging innovators to learn from and connect with world-leading biopharmaceutical companies.

Connect on February 8 | Innovators with small molecule, gene therapy, mRNA, or cell therapy candidates or technology in the therapeutic areas listed below who are actively looking for licensing opportunities are encouraged to apply for a one-on-one virtual meeting with Astellas representatives. Astellas’ target therapeutic areas are:
•    Oncology
•    Immuno-Science
•    Mitochondria Biology
•    Regeneration/Reprogramming

Applications for one-on-one meetings can be found here, and must be submitted by January 7, 2022 at 12:00AM (midnight) ET.

Protection of intellectual property rights (ex. patents, trademarks, copyright, trade secrets, etc.) of your concept is your responsibility and your responsibility alone. Information you include in your application will be shared with State of Possible partners. Please note that these partners did NOT sign Non-Disclosure Agreements (NDAs). Therefore, you should not include any information in your application that you feel could be harmful to your company should that information be disclosed.

 
MassBioHub, 700 Technology Square, 5th Floor Cambridge MA 02139
CEO & President, Axonis
Joanna Stanicka was a research fellow in Prof. Zhigang He laboratory in Boston Children’s Hospital, Harvard Medical School, which discovered PTEN-deletion induced regeneration after optic nerve and spinal cord injury. More recently, this lab also found that KCC2 can restore stepping ability in mice after a spinal cord injury. For the past 7 years, Dr. Stanicka has been studying the signaling pathways that control and stimulate the phenomenon of cell growth in healthy and diseased states. She investigated the molecular mechanisms responsible for cancer, neuroprotection and neuroregeneration. Throughout her career, from undergraduate to postdoctoral research fellow, she has been always interested in how genes and proteins impact the healthy and disease states of the cell and how to apply this knowledge to develop treatments for patients. She has a vision to develop effective treatments for spinal cord injury, and other currently incurable neurological diseases, by using her strong multidisciplinary training in genetics, biochemistry, cell biology and neuroscience, combined with her natural leadership and management skills.

Brought to you by